High-expression of lncRNA CEBPA-AS1 promotes liver cancer progression.
Eur Rev Med Pharmacol Sci
; 23(19): 8295-8302, 2019 Oct.
Article
in En
| MEDLINE
| ID: mdl-31646559
ABSTRACT
OBJECTIVE:
Long non-coding RNAs (lncRNAs) have been confirmed to play important roles in the progression of different cancers. The aim of this study was to detect the expression level of lncRNA CEBPA-AS1 in liver cancer and to study its influence on cell proliferation, invasion and prognosis. PATIENTS ANDMETHODS:
Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, transwell assay, Western blot, Kaplan-Meier survival curve and Cox regression were used to evaluate lncRNA CEBPA-AS1 expression, cell proliferation, invasion, epithelial-mesenchymal transition (EMT)-related molecules expression and prognosis, respectively.RESULTS:
The expression of lncRNA CEBPA-AS1 increased significantly in liver cancer tissues (p<0.05). Meanwhile, CEBPA-AS1 expression was associated with tumor size, portal vein tumor thrombus and invasion and metastasis (p<0.05). In vitro experiments indicated that downregulation of lncRNA CEBPA-AS1 could effectively reduce cell proliferation, invasion and EMT process.CONCLUSIONS:
LncRNA CEBPA-AS1 acts as an oncogene in liver cancer, which may be a novel biomarker in liver cancer progression.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
RNA, Neoplasm
/
Carcinoma, Hepatocellular
/
CCAAT-Enhancer-Binding Proteins
/
RNA, Long Noncoding
/
Liver Neoplasms
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
FARMACOLOGIA
/
TOXICOLOGIA
Year:
2019
Document type:
Article
Affiliation country: